standard biotools inc. - LAB

LAB

Close Chg Chg %
1.14 0.01 0.88%

Closed Market

1.15

+0.01 (0.88%)

Volume: 7.02M

Last Updated:

May 29, 2026, 4:00 PM EDT

Company Overview: standard biotools inc. - LAB

LAB Key Data

Open

$1.12

Day Range

1.10 - 1.19

52 Week Range

0.87 - 1.72

Market Cap

$445.02M

Shares Outstanding

390.37M

Public Float

375.46M

Beta

1.31

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.24

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.09M

 

LAB Performance

1 Week
 
10.68%
 
1 Month
 
21.86%
 
3 Months
 
0.88%
 
1 Year
 
12.87%
 
5 Years
 
N/A
 

LAB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About standard biotools inc. - LAB

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

LAB At a Glance

Standard BioTools, Inc.
50 Milk Street
Boston, Massachusetts 02109
Phone 1-650-266-6000 Revenue 85.33M
Industry Medical Specialties Net Income -74,896,000.00
Sector Health Technology Employees 389
Fiscal Year-end 12 / 2026
View SEC Filings

LAB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.725
Price to Book Ratio 1.166
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.843
Enterprise Value to Sales 3.888
Total Debt to Enterprise Value 0.093

LAB Efficiency

Revenue/Employee 219,359.897
Income Per Employee -192,534.704
Receivables Turnover 6.353
Total Asset Turnover 0.145

LAB Liquidity

Current Ratio 4.194
Quick Ratio 4.01
Cash Ratio 1.732

LAB Profitability

Gross Margin 49.856
Operating Margin -109.345
Pretax Margin -113.326
Net Margin -87.771
Return on Assets -9.97
Return on Equity -13.131
Return on Total Capital -12.925
Return on Invested Capital -12.409

LAB Capital Structure

Total Debt to Total Equity 7.266
Total Debt to Total Capital 6.773
Total Debt to Total Assets 5.43
Long-Term Debt to Equity 5.972
Long-Term Debt to Total Capital 5.567
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Standard Biotools Inc. - LAB

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
97.95M 106.34M 174.43M 85.33M
Sales Growth
-24.99% +8.57% +64.03% -51.08%
Cost of Goods Sold (COGS) incl D&A
60.90M 55.89M 98.43M 42.79M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
15.03M 15.18M 16.86M 6.98M
Depreciation
2.80M 3.40M 12.30M 6.98M
Amortization of Intangibles
- 12.23M 11.78M 4.56M
COGS Growth
-0.51% -8.22% +76.11% -56.53%
Gross Income
37.05M 50.45M 76.01M 42.54M
Gross Income Growth
-46.59% +36.16% +50.66% -44.03%
Gross Profit Margin
+37.83% +47.44% +43.57% +49.86%
2022 2023 2024 2025 5-year trend
SG&A Expense
149.76M 113.49M 210.76M 135.85M
Research & Development
35.00M 25.95M 58.94M 25.99M
Other SG&A
114.76M 87.54M 151.83M 109.86M
SGA Growth
+9.45% -24.22% +85.71% -35.54%
Other Operating Expense
- - - -
-
Unusual Expense
77.30M 13.56M 40.48M 16.94M
EBIT after Unusual Expense
(190.00M) (76.60M) (175.24M) (110.25M)
Non Operating Income/Expense
1.41M 6.96M 40.24M 13.57M
Non-Operating Interest Income
- - 20.20M 9.18M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.33M 4.57M 3.32M 26.00K
Interest Expense Growth
+13.29% +5.45% -27.39% -99.22%
Gross Interest Expense
4.33M 4.57M 3.32M 26.00K
Interest Capitalized
- - - -
-
Pretax Income
(192.93M) (74.20M) (138.31M) (96.70M)
Pretax Income Growth
-203.06% +61.54% -86.39% +30.08%
Pretax Margin
-196.97% -69.78% -79.29% -113.33%
Income Tax
(2.83M) 452.00K 573.00K (37.88M)
Income Tax - Current - Domestic
87.00K 197.00K 233.00K 226.00K
Income Tax - Current - Foreign
405.00K 373.00K 103.00K 666.00K
Income Tax - Deferred - Domestic
- - - (38.36M)
-
Income Tax - Deferred - Foreign
(3.32M) (118.00K) 237.00K (407.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(190.10M) (74.66M) (138.88M) (58.83M)
Minority Interest Expense
- - - -
-
Net Income
(190.10M) (74.66M) (138.88M) (58.83M)
Net Income Growth
-220.91% +60.73% -86.03% +57.64%
Net Margin Growth
-194.08% -70.21% -79.62% -68.94%
Extraordinaries & Discontinued Operations
- - - (16.07M)
-
Discontinued Operations
- - - (16.07M)
-
Net Income After Extraordinaries
(190.10M) (74.66M) (138.88M) (74.90M)
Preferred Dividends
- - - 46.01M
-
Net Income Available to Common
(190.10M) (74.66M) (184.90M) (74.90M)
EPS (Basic)
-2.4277 -0.9431 -0.5234 -0.1963
EPS (Basic) Growth
-210.61% +61.15% +44.50% +62.50%
Basic Shares Outstanding
78.31M 79.16M 353.25M 381.62M
EPS (Diluted)
-2.4277 -0.9431 -0.5234 -0.1963
EPS (Diluted) Growth
-210.61% +61.15% +44.50% +62.50%
Diluted Shares Outstanding
78.31M 79.16M 353.25M 381.62M
EBITDA
(97.68M) (47.86M) (117.90M) (86.32M)
EBITDA Growth
-90.07% +51.00% -146.34% +26.78%
EBITDA Margin
-99.72% -45.01% -67.59% -101.16%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 1.55
Number of Ratings 2 Current Quarters Estimate -0.013
FY Report Date 06 / 2026 Current Year's Estimate -0.10
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.15 Next Fiscal Year Estimate -0.085
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 1 2
Mean Estimate -0.01 -0.01 -0.10 -0.09
High Estimates 0.00 0.01 -0.10 -0.01
Low Estimate -0.03 -0.02 -0.10 -0.16
Coefficient of Variance -190.71 -267.24 N/A -124.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 1 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Standard Biotools Inc. in the News